Holen Sie sich die Stockscreener-App
46.06
1.21%
0.55
Handel nachbörslich:
46.50
0.44
+0.96%
Schlusskurs vom Vortag:
$45.51
Offen:
$46.42
24-Stunden-Volumen:
26.84M
Relative Volume:
1.33
Marktkapitalisierung:
$68.46B
Einnahmen:
$20.62B
Nettoeinkommen (Verlust:
$3.56B
KGV:
19.31
EPS:
2.3847
Netto-Cashflow:
$3.48B
1W Leistung:
+6.65%
1M Leistung:
+4.14%
6M Leistung:
-50.89%
1J Leistung:
-56.48%
1-Tages-Spanne:
$45.81
$47.16
1-Wochen-Bereich:
$42.50
$47.16
52-Wochen-Spanne:
$42.20
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Firmenname
Boston Scientific Corp
Sektor
Branche
Telefon
508-683-4000
Adresse
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
46.06 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
ABT
Abbott Laboratories
|
107.27 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
346.60 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
86.88 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
EW
Edwards Lifesciences Corp
|
83.68 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-30 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-10-03 | Herabstufung | Erste Group | Buy → Hold |
| 2025-09-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-16 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-16 | Hochstufung | Needham | Hold → Buy |
| 2025-01-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Herabstufung | Needham | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-20 | Fortgesetzt | Citigroup | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-05-27 | Hochstufung | Needham | Hold → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-26 | Herabstufung | Needham | Buy → Hold |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-17 | Eingeleitet | Truist | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Buy |
| 2019-12-30 | Bestätigt | Cowen | Outperform |
| 2019-12-19 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-09-05 | Fortgesetzt | JP Morgan | Overweight |
| 2019-09-03 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-10-02 | Bestätigt | Morgan Stanley | Overweight |
| 2018-09-07 | Bestätigt | Needham | Strong Buy |
| 2018-09-04 | Hochstufung | Jefferies | Hold → Buy |
| 2018-07-06 | Bestätigt | Needham | Strong Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-04-26 | Bestätigt | Needham | Strong Buy |
Alle ansehen
Boston Scientific Corp Aktie (BSX) Neueste Nachrichten
Boston Scientific earnings on deck as WATCHMAN slowdown looms By Investing.com - Investing.com Canada
UBS lowers Boston Scientific stock price target on valuation reset By Investing.com - Investing.com Canada
Boston Scientific Restructures Operations, Plans Workforce Cuts - Medical Product Outsourcing
Implicity’s Next-Generation ILR ECG Analyzer Earns FDA Clearance - GlobeNewswire Inc.
Canaccord reiterates Boston Scientific stock rating after restructuring - Investing.com
Boston Scientific Corp (BSX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fears for Irish jobs as Boston Scientific plans global restructuring - Business Post
What To Expect From Boston Scientific’s (BSX) Q2 Earnings - Barchart.com
Boston Scientific Announces 2026 Global Restructuring Plan to Drive Cost Efficiencies and Growth - Minichart
Boston Scientific to restructure, cut costs by $500M annually - NBC Boston
Fed. Circ. Clears Boston Scientific In $49M Stent Patent Case - Law360
Boston Scientific unveils new restructuring plan, expects job cuts - Reuters
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
Boston Scientific (NYSE: BSX) sets $700–$800 million restructuring with $500 million savings - Stock Titan
Boston Scientific Overturns $42M Patent Verdict - Intellectia AI
Boston Scientific Gets $42 Million Stent Patent Verdict Reversed - Bloomberg Law News
Here's How Much $100 Invested In Boston Scientific 15 Years Ago Would Be Worth Today - Benzinga
Boston Scientific Corp (BSX) Cash Flow - TradingKey
Boston Scientific Corporation (BSX) Options Chain - Yahoo! Finance Canada
Boston Scientific Corp (BSX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Boston Scientific Corp (BSX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Boston Scientific (BSX) Faces FDA Advisory Over Transcarotid Sys - GuruFocus
Boston Scientific (BSX) Faces Potential Device Risk Notification - GuruFocus
Boston Scientific Corp (BSX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Boston Scientific Corp (BSX) Institutional Confidence - TradingKey
Boston Scientific Corp (BSX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Electrosurgery Market Projected to Reach $11.59 Billion by 2031 as Demand for Minimally Invasive Procedures Rises - GlobeNewswire Inc.
BSX|Boston Scientific Corp|Price:45.500|Chg%:+1.250 - TradingKey
BSX|Boston Scientific Corp|Price:44.265|Chg%:+0.685 - TradingKey
Boston Scientific stock trades firm as cardiovascular revenue grows and TAVR momentum supports earni - AD HOC NEWS
Daily Brief Health Care: Boston Scientific, Mitesco Inc, Samsung Biologics and more - Smartkarma
Boston Scientific (BSX) Enrolls First Patients In Global Faraflex AFib Trial - Yahoo! Finance Canada
AAFMAA Wealth Management & Trust LLC's Boston Scientific Corp(BSX) Holding History - GuruFocus
Boston Scientific stock trades steady as recent earnings and cardiovascular portfolio shape investor - AD HOC NEWS
Boston Scientific Settles With Stryker In Spine Device IP Fight - Law360
Goldman Sachs Launches $510 Million Autocallable Notes Linked to Boston Scientific Stock Performance - Kalkine Media
Boston Scientific Corporation (BSX) Stock forecasts - Yahoo Finance UK
Boston Scientific, Stryker Settle Surgical Device Patent Dispute - Bloomberg Law News
Boston Scientific (BSX) Stock Still Looks Undervalued Following Its 58% Slump - Yahoo Finance
Boston Scientific stock trades steadily as device maker grows revenue and prepares for next earnings - Ad-hoc-news.de
Boston Scientific (BSX) Recalls Put Focus On Whether The Stock Still Looks Undervalued - Yahoo Finance
Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Boston Scientific Corp. stock outperforms competitors despite losses on the day - MarketWatch
Boston Scientific's Q2 Earnings Coming Up: Buy, Hold or Sell the Stock? - Yahoo Finance
Boston Scientific stock advances on strong sales and margin gains - Ad-hoc-news.de
Boston Scientific to Combine Light Manufacturing, Global Distribution in Indiana Expansion - Assembly Magazine
Boston Scientific stock holds gains as cardiovascular revenue grows and new devices support long ter - Ad-hoc-news.de
Boston Scientific Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Boston Scientific Corp Investor Event at the Scientific Session of the American College of Cardiology Transcript - GuruFocus
Boston Scientific stock trades steady as latest earnings highlight growth and margin focus - ad-hoc-news.de
The Bull Case For Boston Scientific (BSX) Could Change Following Global Recall Of CRE Endoscopy Devices - simplywall.st
Finanzdaten der Boston Scientific Corp-Aktie (BSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):